Gilead's Dan O'Day on 1Q23 Earnings

blonca9
Apr 27, 2023
1 min read

Updated: Jun 16, 2023

BiotechTV's exclusive interview with Gilead Sciences' Chairman & CEO Dan O'Day on the company's Q1 2023 earnings day.

Brad Loncar visited Gilead Science's headquarters in Foster City, California and had the opportunity to interview Chairman and CEO Dan O'Day about Gilead’s business.

Discussed:

- Gilead’s transformation into oncology and other areas.

- The business model of cell therapy.

- The competitive landscape for the ADC medicine Trodelvy.

- Other oncology targets like CD47 and TIGIT.

- Long-acting medicines for HIV.

- What it was like to develop remdesivir during the pandemic.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Gilead's Dan O'Day on 1Q23 Earnings

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight